NAS:BSTC (USA) Also trade in: Germany

BioSpecifics Technologies Corp

$ 57.9 1.73 (3.08%)
Volume: 40,628 Avg Vol (1m): 68,171
Market Cap $: 421.91 Mil Enterprise Value $: 337.39 Mil
P/E (TTM): 21.29 P/B: 4.15
Earnings Power Value -8.13
Net Current Asset Value 13.33
Tangible Book 13.87
Projected FCF 34.99
Median P/S Value 64.71
Graham Number 29.13
Peter Lynch Value 68
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
99.07% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BSTC: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.06, Med: 10000, Max: 10000
Current: 10000
0.06
10000
Equity-to-Asset 0.97
Equity-to-Asset ranked higher than
96.07% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
BSTC: 0.97
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -5.34, Med: 0.85, Max: 0.98
Current: 0.97
-5.34
0.98
Interest Coverage No Debt
Interest Coverage ranked higher than
99.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
BSTC: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 68.72
DISTRESS
GREY
SAFE
Beneish M-Score -2.66
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 97.79%
WACC 5.1%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 69.03
Operating Margin ranked higher than
97.60% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
BSTC: 69.03
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -68.6, Med: 52.2, Max: 70.99
Current: 69.03
-68.6
70.99
Net Margin % 59.99
Net Margin ranked higher than
95.58% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
BSTC: 59.99
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -62.01, Med: 38.96, Max: 60.84
Current: 59.99
-62.01
60.84
ROE % 21.66
ROE ranked higher than
92.11% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BSTC: 21.66
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -31.9, Med: 20.47, Max: 61.21
Current: 21.66
-31.9
61.21
ROA % 20.98
ROA ranked higher than
95.11% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BSTC: 20.98
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -15.92, Med: 18.9, Max: 47.52
Current: 20.98
-15.92
47.52
ROC (Joel Greenblatt) % 160.33
ROC (Joel Greenblatt) ranked higher than
96.53% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BSTC: 160.33
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -321400, Med: 208.11, Max: 486.39
Current: 160.33
-321400
486.39
3-Year Total Revenue Growth Rate 13.20
3-Year Revenue Growth Rate ranked higher than
79.26% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
BSTC: 12.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -46.8, Med: 8.55, Max: 65.2
Current: 12.8
-46.8
65.2
3-Year Total EBITDA Growth Rate 18.90
3-Year EBITDA Growth Rate ranked higher than
86.03% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BSTC: 18.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -16.3, Max: 41.7
Current: 18.6
0
41.7
3-Year EPS w/o NRI Growth Rate 27.40
3-Year EPS w/o NRI Growth Rate ranked higher than
80.21% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
BSTC: 27.4
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 104.1
Current: 27.4
0
104.1

» BSTC's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BSTC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XKRX:141080 XSWX:BSLN XSWX:SKIN SHSE:600556 NAS:NXTC XKRX:031390 NAS:SVA XKRX:001630 XKRX:005690 XKRX:048530 NAS:SIGA NAS:TBIO NAS:KRYS XKRX:196170 WAR:CLN NAS:CRBP NAS:REPL XKRX:078160 XKRX:228760 XKRX:199800
Traded in other countries 1B3.Germany
Address 35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive cabsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Ratios

Current vs industry vs history
PE Ratio (TTM) 21.29
PE Ratio ranked lower than
50.81% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
BSTC: 21.29
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 15.05, Med: 31.52, Max: 88.33
Current: 21.29
15.05
88.33
Forward PE Ratio 18.73
Forward P/E ranked higher than
58.44% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
BSTC: 18.73
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 21.29
PE without NRI ranked lower than
51.03% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
BSTC: 21.29
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 15.05, Med: 31.52, Max: 88.33
Current: 21.29
15.05
88.33
PB Ratio 4.15
PB Ratio ranked lower than
50.83% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
BSTC: 4.15
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.49, Med: 6.97, Max: 571.43
Current: 4.15
3.49
571.43
PS Ratio 12.79
PS Ratio ranked lower than
52.48% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
BSTC: 12.79
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 7.84, Med: 14.29, Max: 75.09
Current: 12.79
7.84
75.09
Price-to-Free-Cash-Flow 17.24
Price-to-Free-Cash-Flow ranked lower than
51.32% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
BSTC: 17.24
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.9, Med: 37.92, Max: 3552.86
Current: 17.24
13.9
3552.86
Price-to-Operating-Cash-Flow 17.24
Price-to-Operating-Cash-Flow ranked lower than
61.90% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
BSTC: 17.24
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 13.9, Med: 37.92, Max: 3552.86
Current: 17.24
13.9
3552.86
EV-to-EBIT 14.69
EV-to-EBIT ranked higher than
59.39% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BSTC: 14.69
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -152, Med: 17.8, Max: 55
Current: 14.69
-152
55
EV-to-EBITDA 13.59
EV-to-EBITDA ranked higher than
60.14% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BSTC: 13.59
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -155.7, Med: 16.8, Max: 54.3
Current: 13.59
-155.7
54.3
EV-to-Revenue 10.15
EV-to-Revenue ranked higher than
55.38% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
BSTC: 10.15
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 7, Med: 12.4, Max: 75.9
Current: 10.15
7
75.9
PEG Ratio 0.73
PEG Ratio ranked higher than
71.30% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
BSTC: 0.73
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.7, Med: 0.84, Max: 1.11
Current: 0.73
0.7
1.11
Shiller PE Ratio 54.74
Shiller PE Ratio ranked lower than
67.44% of 86 companies
in the Biotechnology industry.
Industry Max: 11472.38, Med: 42.91, Min: 0.02
BSTC: 54.74
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 46.29, Med: 107.18, Max: 1349
Current: 54.74
46.29
1349
Current Ratio 27.10
Current Ratio ranked higher than
89.57% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BSTC: 27.1
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.43, Med: 7.32, Max: 48.41
Current: 27.1
0.43
48.41
Quick Ratio 27.10
Quick Ratio ranked higher than
89.76% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BSTC: 27.1
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.41, Med: 6.23, Max: 48.41
Current: 27.1
0.41
48.41
Days Sales Outstanding 180.90
Days Sales Outstanding ranked lower than
95.36% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
BSTC: 180.9
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 40.88, Med: 115.13, Max: 182.93
Current: 180.9
40.88
182.93

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.00
3-Year Share Buyback Rate ranked higher than
86.46% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BSTC: -2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -6, Med: -2, Max: 2.5
Current: -2
-6
2.5

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.17
Price-to-Tangible-Book ranked higher than
56.82% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
BSTC: 4.17
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.59, Med: 4.93, Max: 542.86
Current: 4.17
0.59
542.86
Price-to-Projected-FCF 1.65
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
65.28% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
BSTC: 1.65
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.52, Med: 2.58, Max: 364.29
Current: 1.65
0.52
364.29
Price-to-Median-PS-Value 0.89
Price-to-Median-PS-Value ranked higher than
52.21% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
BSTC: 0.89
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.04, Med: 0.64, Max: 4.7
Current: 0.89
0.04
4.7
Price-to-Peter-Lynch-Fair-Value 0.85
Price-to-Peter-Lynch-Fair-Value ranked higher than
64.06% of 64 companies
in the Biotechnology industry.
Industry Max: 13.37, Med: 1.72, Min: 0.02
BSTC: 0.85
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.61, Med: 1.15, Max: 3.3
Current: 0.85
0.61
3.3
Price-to-Graham-Number 1.99
Price-to-Graham-Number ranked lower than
50.50% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
BSTC: 1.99
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.87, Med: 2.78, Max: 11.69
Current: 1.99
0.87
11.69
Earnings Yield (Joel Greenblatt) % 6.81
Earnings Yield (Greenblatt) ranked higher than
90.29% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BSTC: 6.81
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5.6, Med: 4.3, Max: 7.7
Current: 6.81
-5.6
7.7
Forward Rate of Return (Yacktman) % 23.26
Forward Rate of Return ranked higher than
87.41% of 135 companies
in the Biotechnology industry.
Industry Max: 107.61, Med: 11.41, Min: -475.79
BSTC: 23.26
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -0.2, Med: 22, Max: 23.4
Current: 23.26
-0.2
23.4

More Statistics

Revenue (TTM) (Mil) $ 33.25
EPS (TTM) $ 2.72
Beta 0.5
Volatility % 28.33
52-Week Range $ 40.58 - 73.31
Shares Outstanding (Mil) 7.29

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N